CN103748222B - 新型抗人ngf抗体 - Google Patents

新型抗人ngf抗体 Download PDF

Info

Publication number
CN103748222B
CN103748222B CN201280039293.3A CN201280039293A CN103748222B CN 103748222 B CN103748222 B CN 103748222B CN 201280039293 A CN201280039293 A CN 201280039293A CN 103748222 B CN103748222 B CN 103748222B
Authority
CN
China
Prior art keywords
fab
fragment
antibody
human
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280039293.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN103748222A (zh
Inventor
蒲原正纯
田中祐嗣
神谷由香里
高崎淳
米泽敦夫
吉见英治
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yamanouchi Pharmaceutical Co Ltd
Original Assignee
Yamanouchi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Pharmaceutical Co Ltd filed Critical Yamanouchi Pharmaceutical Co Ltd
Publication of CN103748222A publication Critical patent/CN103748222A/zh
Application granted granted Critical
Publication of CN103748222B publication Critical patent/CN103748222B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201280039293.3A 2011-08-11 2012-08-10 新型抗人ngf抗体 Expired - Fee Related CN103748222B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2011176209 2011-08-11
JP2011-176209 2011-08-11
JP2011269215 2011-12-08
JP2011-269215 2011-12-08
PCT/JP2012/070433 WO2013022083A1 (ja) 2011-08-11 2012-08-10 新規抗ヒトｎｇｆ抗体

Publications (2)

Publication Number Publication Date
CN103748222A CN103748222A (zh) 2014-04-23
CN103748222B true CN103748222B (zh) 2015-07-22

Family

ID=47668585

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280039293.3A Expired - Fee Related CN103748222B (zh) 2011-08-11 2012-08-10 新型抗人ngf抗体

Country Status (30)

Country Link
US (2) US8986952B2 (enExample)
EP (1) EP2743348B1 (enExample)
JP (1) JP5376095B2 (enExample)
KR (1) KR101999867B1 (enExample)
CN (1) CN103748222B (enExample)
AR (1) AR087506A1 (enExample)
AU (1) AU2012293161B2 (enExample)
BR (1) BR112014002576B1 (enExample)
CA (1) CA2841181C (enExample)
CY (1) CY1119914T1 (enExample)
DK (1) DK2743348T3 (enExample)
EA (1) EA024292B1 (enExample)
ES (1) ES2663968T3 (enExample)
HR (1) HRP20180155T1 (enExample)
HU (1) HUE036079T2 (enExample)
IL (1) IL230797A (enExample)
IN (1) IN2014CN00614A (enExample)
LT (1) LT2743348T (enExample)
ME (1) ME02944B (enExample)
MX (1) MX351273B (enExample)
NO (1) NO2743348T3 (enExample)
PH (1) PH12014500001A1 (enExample)
PL (1) PL2743348T3 (enExample)
PT (1) PT2743348T (enExample)
RS (1) RS56876B1 (enExample)
SI (1) SI2743348T1 (enExample)
SM (1) SMT201800166T1 (enExample)
TW (1) TWI554519B (enExample)
WO (1) WO2013022083A1 (enExample)
ZA (1) ZA201400741B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
WO2012075340A2 (en) 2010-12-01 2012-06-07 Alderbio Holdings Llc Anti-ngf compositions and use thereof
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
JP6135161B2 (ja) * 2013-02-08 2017-05-31 アステラス製薬株式会社 新規抗ヒトｎｇｆ抗体
US9127055B2 (en) 2013-02-08 2015-09-08 Astellas Pharma Inc. Method of treating pain with anti-human NGF antibody
BR112017025029A2 (pt) * 2015-05-22 2018-08-07 Astellas Pharma Inc. ?novo fragmento fab de anticorpo ngf anti- humano?.
JPWO2017164349A1 (ja) * 2016-03-25 2019-02-07 アステラス製薬株式会社 ＰＥＧ化抗ヒトＮＧＦ抗体Ｆａｂ’フラグメント含有医薬組成物
CN114751982B (zh) * 2017-12-15 2023-06-23 安源医药科技（上海）有限公司 抗人ngf抗体及其制备方法和用途
US20210147529A1 (en) 2018-05-15 2021-05-20 Astellas Pharma Inc. Pharmaceutical composition for suppressing atrial fibrillation having as active ingredient anti-human ngf antibody or antigen-binding fragment thereof
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0690132A1 (en) * 1993-03-11 1996-01-03 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Anti-hiv monoclonal antibody
CN101827609A (zh) * 2007-08-10 2010-09-08 里珍纳龙药品有限公司 抗人神经生长因子的高亲和力人抗体

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CN1684708A (zh) 2001-05-30 2005-10-19 基因技术股份有限公司 抗ngf抗体用于治疗各种疾病
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
CN101014364B (zh) 2002-12-24 2012-01-18 里纳特神经系统学公司 抗ngf抗体及其使用方法
EA013614B1 (ru) 2003-07-15 2010-06-30 Амджен Инк. Изолированное антитело к фактору роста нервов (ngf) и способы его применения
ITRM20030601A1 (it) 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
NZ556157A (en) 2005-01-24 2009-09-25 Elan Pharma Int Ltd Specific binding members for NGF
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
RU2461551C2 (ru) 2007-10-24 2012-09-20 Астеллас Фарма Инк. Азолкарбоксамидное соединение или его фармацевтически приемлемая соль
US8435523B2 (en) 2009-05-04 2013-05-07 Abbott Research B.V. Antibodies against nerve growth factor (NGF) with enhanced in vivo stability

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0690132A1 (en) * 1993-03-11 1996-01-03 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Anti-hiv monoclonal antibody
CN101827609A (zh) * 2007-08-10 2010-09-08 里珍纳龙药品有限公司 抗人神经生长因子的高亲和力人抗体

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AAA51016.1;Pascual et al;《GenBank》;20030417;第1-2页 *
BAC01733.1;Akahori et al;《GenBank》;20020702;第1-3页 *
Fate of novel painkiller mAbs hangs in balance;Garber Ken et al;《Nature Biotechnology》;20110331;第29卷(第3期);第173-175页 *
神经生长因子抗体的制备及其应用;赵小林等;《中国神经科学杂志》;20040331;第20卷(第2期);第171-173页 *

Also Published As

Publication number Publication date
CA2841181C (en) 2022-01-25
HUE036079T2 (hu) 2018-06-28
AR087506A1 (es) 2014-03-26
IN2014CN00614A (enExample) 2015-04-03
US8986952B2 (en) 2015-03-24
MX351273B (es) 2017-10-06
CY1119914T1 (el) 2018-06-27
LT2743348T (lt) 2018-05-10
CA2841181A1 (en) 2013-02-14
NO2743348T3 (enExample) 2018-06-09
JPWO2013022083A1 (ja) 2015-03-05
EA024292B1 (ru) 2016-09-30
IL230797A0 (en) 2014-03-31
ES2663968T3 (es) 2018-04-17
SMT201800166T1 (it) 2018-05-02
SI2743348T1 (en) 2018-04-30
PL2743348T3 (pl) 2018-04-30
US20150218265A1 (en) 2015-08-06
CN103748222A (zh) 2014-04-23
KR101999867B1 (ko) 2019-07-12
TWI554519B (zh) 2016-10-21
EP2743348B1 (en) 2018-01-10
IL230797A (en) 2017-06-29
JP5376095B2 (ja) 2013-12-25
EA201490433A1 (ru) 2014-05-30
ZA201400741B (en) 2014-11-26
EP2743348A1 (en) 2014-06-18
BR112014002576A2 (pt) 2021-01-12
EP2743348A4 (en) 2015-04-29
HRP20180155T1 (hr) 2018-03-23
TW201319086A (zh) 2013-05-16
DK2743348T3 (en) 2018-02-26
ME02944B (me) 2018-04-20
BR112014002576B1 (pt) 2022-08-23
PH12014500001A1 (en) 2014-02-10
PT2743348T (pt) 2018-02-23
US20140155582A1 (en) 2014-06-05
AU2012293161B2 (en) 2017-04-27
AU2012293161A1 (en) 2014-02-06
KR20140047116A (ko) 2014-04-21
WO2013022083A1 (ja) 2013-02-14
RS56876B1 (sr) 2018-04-30
MX2014001627A (es) 2014-05-28

Similar Documents

Publication Publication Date Title
CN103748222B (zh) 新型抗人ngf抗体
US9127055B2 (en) Method of treating pain with anti-human NGF antibody
JP2016000731A (ja) 二重特異性ｅｇｆｒ／ｉｇｆｉｒ結合分子
CN114269389B (zh) 靶向紧密连接蛋白18.2的抗体药物偶联物
MX2013009859A (es) Ligandos dr3 antagonicos.
CN106687478A (zh) 新的抗人Tie‑2抗体
JP2021520195A (ja) Ｃ３結合薬及びその使用方法
ES2665851T3 (es) Nuevo anticuerpo anti-CTGF humano
TWI432453B (zh) 改良型人化抗人α９整連蛋白抗體
JP6700620B2 (ja) 新規抗ヒトＮＧＦ抗体Ｆａｂフラグメント
JP6135161B2 (ja) 新規抗ヒトｎｇｆ抗体
WO2011004847A1 (ja) 新規ヒト化抗ヒトα９インテグリン抗体
HK40090814A (zh) 靶向紧密连接蛋白18.2的抗体药物偶联物
HK1234078B (zh) 新的抗人tie-2抗体

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150722

CF01 Termination of patent right due to non-payment of annual fee